

Guo's Aortic Arch Reconstruction: A Multicenter, Prospective Study of the Novel WeFlow-Tribranch System (GENIUS Study)

NCT06385379

Status	RECRUITING
Phase	Not Applicable
Sponsor	Hangzhou Endonom Medtech Co., Ltd.
Enrollment	90 participants

Key Eligibility Criteria

Inclusion (10)

- Patients aged 18 to 80 years old;
- Diagnosed with aortic arch lesions requiring intervention, including true aortic arch aneurysms, pseudo-aortic arch aneurysms, and ulcers involving the aortic arch;
- Showing a suitable vascular condition, including:
 - Ascending aorta length greater than 50 mm (from the aortic sinusoid junction to the proximal cardiac margin of the innominate artery).
 - Ascending aorta diameter e 24 mm and d 48 mm;
- ... and 5 more (see full listing online)

Exclusion (16)

- Experienced systemic infection during past three months;
- Neck surgery was performed within 3 months;
- Previous endovascular interventional treatment involving the aortic arch was performed;
- Infectious aortic disease, Takayasu arteritis, Marfan syndrome (or other connective tissue diseases);
- Severe stenosis, calcification, thrombosis, or tortuosity of the branch artery to be reconstructed;
- ... and 11 more (see full listing online)

Locations (20 total)

Beijing Anzhen Hospital, Capital Medical University, Beijing, China
Chinese PLA General Hospital, Beijing, China
The First Hospital of Jilin University, Changchun, China
... and 17 more locations